齐拉西酮治疗奥氮平致体重增加精神分裂症患者的效果和安全性

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effeet and safety of Ziprasidone in the treatment of Olanzapine-indueed body weight gain in patients with sehizophrenia.Methods From January 2016 to January 2018，a total of 84 sehizophrenie patients admitted to our hospital were seleeted as study subjeets.They were divided into experimental group and referenee group aeeording to random number table method，with 42 eases in eaeh group.The referenee group was treated with Olanzapine and the experimental group was treated with Ziprasidone eombined with Olanzapine.After 8 weeks of treatment，positive and negative symptom seale（PANSS）and psyehiatrie adverse reaetion seale（UKU）were used to evaluate the therapeutie effeet and adverse reaetions of the two groups.And body weight，body mass index（BMI），fasting blood glueose（GLU），triglyeeride（TG），total eholesterol（TC），high density lipoprotein（HDL），and low density lipoprotein（LDL）were observed before and after treatment.Results There were no signifieant differenees in PANSS seores between the two groups before treatment（P＞0.05）.The PANSS seores after treatment in the two groups were signifieantly lower than those before treatment，and the differenees were statistieally signifieant（P＜0.05）.There were no signifieant differenees in PANSS seores between the two groups after treatment（P＞0.05）.There were no signifieant differenees in body weight，BMI，GLU，TG，TC，HDL and LDL between the two groups before treatment（P＞0.05）.The body weight，BMI，GLU，TG，TC，HDL and LDL after treatment in the referenee group were higher than those before treatment，and the differenees were statistieally signifieant（P＜0.05）.There were no signifieant differenees in body weight，BMI，GLU，TG，TC，HDL and LDL before and after treatment in the experimental group（P＞0.05）.The weight，BMI，GLU，TG，TC and LDL after treatment in the experimental group were lower than those in the referenee group，and the differenees were statistieally signifieant（P＜0.05）.There was no signifieant differenee in the total ineidenee rate of adverse reaetions between the two groups（P＞0.05）.ConclusionZiprasidone ean improve the disorder of glyeolipid metabolism indueed by Olanzapine，thus effeetively prevent the inerease of body weight，and the safety is relatively high，whieh is worthy of elinieal promotion and applieation.

Key words： Sehizophrenia Olanzapine Weight gain Metabolie disorders Ziprasidone

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SONG Xin-hong
	HE Shou-bin

Cite this article:

SONG Xin-hong,HE Shou-bin. Effect and safety of Ziprasidone in the treatment of Olanzapine-induced body weight gain in patients with schizophrenia[J]. 中国当代医药, 2019, 26(1): 91-93转97.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I1/91

［1］	高长青，杨丽苹.齐拉西酮与奥氮平对初诊精神分裂症患者急性期的疗效和代谢影响对比观察［J］.中外医疗，2016，35（17）：127-128.
［2］	苏力.齐拉西酮与奥氮平治疗老年精神分裂症疗效及对血糖、血脂水平的影响分析［J］.中国实用医药，2018，26（9）：137-139.
［3］	王小娜，金韬.齐拉西酮与奥氮平治疗首发精神分裂症的临床观察［J］.重庆医学，2014，19（26）：3527-3529.
［4］	邓旭瑶，卓恺明.齐拉西酮和奥氮平对首发精神分裂症患者疗效及对血糖血脂的影响［J］.山西医药杂志，2016，45（13）：1580-1582.
［5］	吴旭东.奥氮平与齐拉西酮对首发精神分裂症糖脂代谢影响的对照研究［J］.海峡药学，2016，28（5）：74-76.
［6］	世界卫生组织.疾病和有关健康问题的国际统计分类（ICD-10）［M］.北京世界卫生组织合作中心.北京：人民卫生出版社，2015：109.
［7］	蔡东滨，杨欣湖，郑伟，等.预防抗精神病药物所致首发精神分裂症患者体重增加的研究现况［J］.四川精神卫生，2017，30（2）：191-195.
［8］	张静，韩笑乐，辛立敏，等.奥氮平和利培酮治疗精神分裂症合并慢性乙肝患者的疗效分析及其对糖脂代谢的影响［J］.中国新药杂志，2017，25（1）：66-69.
［9］	许雪莲.奥氮平与利培酮治疗老年女性精神分裂症患者的疗效及其对糖脂代谢的影响［J］.齐齐哈尔医学院学报，2015，36（17）：2557-2558.
［10］	王章元，贾小玲，张青青，等.齐拉西酮和奥氮平对老年精神分裂症患者脂糖代谢的影响［J］.中国老年学，2016，36（9）：2242-2244.
［11］	龙珊珊，雷秀萍，余寒，等.齐拉西酮与奥氮平在精神分裂症患者中的疗效对比观察及糖脂代谢安全性研究［J］.国际精神病学杂志，2017，44（6）：984-986.
［12］	吴昊.齐拉西酮与奥氮平治疗首发精神分裂症对比观察［J］.当代医学，2015，25（7）：124-125.
［13］	张涛.齐拉西酮治疗奥氮平所致体质量增加临床评价［J］.中国药业，2017，26（18）：72-74.
［14］	褚凤军.齐拉西酮与奥氮平治疗老年精神分裂症的疗效及对糖脂代谢的影响比较研究［J］.中国民康医学，2018，24（1）：254-256.
［15］	王海华，姚琳，潘丽红.奥氮平合并齐拉西酮及行为干预对精神分裂症患者体质量和糖脂代谢的影响［J］.临床精神医学杂志，2016，26（1）：44-46.
［16］	梁启勇，苏冠环，陈梓朗.门诊首发精神分裂症应用齐拉西酮和利培酮治疗的疗效观察［J］.中国医药科学，2018，8（2）：33-35.